- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05126160
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Xiaozhong Chen
- Phone Number: +86 0571-88128202
- Email: cxzfyun@sina.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Recruiting
- Renmin Hospital of Wuhan University
-
Contact:
- Xiangpan Li
- Email: rm001227@whu.edu.cn
-
Principal Investigator:
- Xiangpan Li
-
Sub-Investigator:
- Qingqing Li
-
-
Ningbo
-
Ningbo, Ningbo, China, 315000
- Recruiting
- Ningbo First Hospital
-
Principal Investigator:
- Pengrong Lou
-
Sub-Investigator:
- Jianliang Zhou
-
Ningbo, Ningbo, China, 315000
- Recruiting
- Ningbo medical center lihuili hospital
-
Contact:
- Miaozhen Lu
- Email: lmz2005@yeah.net
-
Principal Investigator:
- Miaozhen Lu
-
Sub-Investigator:
- Yanping Bei
-
-
Wenzhou
-
Wenzhou, Wenzhou, China, 325000
- Recruiting
- The First Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Changlin Zou
- Email: zcl19670115@163.com
-
Principal Investigator:
- Changlin Zou
-
Sub-Investigator:
- Raoying Xie
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
Contact:
- Xiaozhong Chen
- Phone Number: +86 571-88128202
- Email: cxzfyun@sina.com
-
Sub-Investigator:
- Caineng Cao
-
Sub-Investigator:
- Lei Wang
-
Sub-Investigator:
- Shuang Huang
-
Sub-Investigator:
- Mengyun Qiang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma.
ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC >4*109/L, HGB>90G/L, and PLT>100*109/L. Written informed consent
Exclusion Criteria:
Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), or emotional disturbance.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under Curve (AUC)
Time Frame: Median follow-up time of 5 years for the whole group
|
The AUC of the immune score based radiomic staging system
|
Median follow-up time of 5 years for the whole group
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Xiaozhong Chen, Department of Radiation Oncology, Zhejiang Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Nasopharyngeal Neoplasms
- Carcinoma
- Nasopharyngeal Carcinoma
Other Study ID Numbers
- ZJCH-2021-NPC01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasopharyngeal Carcinoma
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditionsUnited States, Canada, China, Singapore
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharynx Carcinoma | Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal Nonkeratinizing CarcinomaUnited States, Singapore, China
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedStage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal...United States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing... and other conditionsUnited States, Canada, Australia
-
Alain AlgaziAstraZeneca; Incyte CorporationWithdrawnRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma | Epstein-Barr Virus Positive | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma
-
Alliance for Clinical Trials in OncologyNot yet recruitingRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownLOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNTFrance
-
Stanford UniversityTerminatedStage IV Nasopharyngeal Carcinoma | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Carcinoma | Stage 0 Nasopharyngeal Carcinoma | Stage 0 Paranasal Sinus Cancer | Stage I Nasopharyngeal Carcinoma | Stage I Paranasal... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IV Nasopharyngeal Carcinoma AJCC v8 | Stage II Nasopharyngeal Carcinoma AJCC v8 | Stage III Nasopharyngeal Carcinoma AJCC v8
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
Clinical Trials on Immune Score Based Radiomics
-
Maastricht UniversityRadboud University Medical Center; University of California, San FranciscoUnknownNonsmall Cell Lung CancerNetherlands
-
Shanghai Pulmonary Hospital, Shanghai, ChinaZunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...RecruitingLung Adenocarcinoma | Radiomics | Grading SystemChina
-
Fudan UniversityUnknownColorectal Cancer Stage I-IVChina
-
First Affiliated Hospital of Chongqing Medical...Recruiting
-
Fudan UniversityCompletedThe Patients With CRLM Who Benefit More From BevacizumabChina
-
Rutgers, The State University of New JerseyRecruitingIatrogenic Disease | Risk ReductionUnited States
-
Helsinki University Central HospitalRecruiting
-
Seoul National University HospitalKorea Health Industry Development Institute; Dong-A University; Inha University... and other collaboratorsNot yet recruitingHospital Rapid Response Team | Hospital Medical Emergency Team
-
Ramsay Générale de SantéEuropean Clinical Trial Experts NetworkCompletedEhlers-Danlos SyndromeFrance
-
Region StockholmRecruiting